<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22937736</article-id><article-id pub-id-type="pmc">3488323</article-id><article-id pub-id-type="publisher-id">1745-6215-13-156</article-id><article-id pub-id-type="doi">10.1186/1745-6215-13-156</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Chang</surname><given-names>Anne B</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>annechang@ausdoctors.net</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Grimwood</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>k.grimwood@uq.edu.au</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Robertson</surname><given-names>Colin F</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>colin.robertson@rch.org.au</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Wilson</surname><given-names>Andrew C</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Andrew.Wilson@health.wa.gov.au</email></contrib><contrib contrib-type="author" id="A5"><name><surname>van Asperen</surname><given-names>Peter P</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>peter.vanasperen@health.nsw.gov.au</email></contrib><contrib contrib-type="author" id="A6"><name><surname>O&#x02019;Grady</surname><given-names>Kerry-Ann F</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>k.ogrady@uq.edu.au</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Sloots</surname><given-names>Theo P</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>t.sloots@uq.edu.au</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Torzillo</surname><given-names>Paul J</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>pault@med.usyd.edu.au</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Bailey</surname><given-names>Emily J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>e.bailey1@uq.edu.au</email></contrib><contrib contrib-type="author" id="A10"><name><surname>McCallum</surname><given-names>Gabrielle B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Gabrielle.McCallum@menzies.edu.au</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Masters</surname><given-names>Ian B</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>brent_masters@health.qld.gov.au</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Byrnes</surname><given-names>Catherine A</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>c.byrnes@auckland.ac.nz</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Chatfield</surname><given-names>Mark D</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>mark.chatfield@menzies.edu.au</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Buntain</surname><given-names>Helen M</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>helen_buntain@health.qld.gov.au</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Mackay</surname><given-names>Ian M</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>ian.mackay@uq.edu.au</email></contrib><contrib contrib-type="author" id="A16"><name><surname>Morris</surname><given-names>Peter S</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I11">11</xref><email>Peter.Morris@menzies.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia</aff><aff id="I2"><label>2</label>Queensland Children&#x02019;s Respiratory Centre, Royal Children&#x02019;s Hospital, Brisbane, QLD, Australia</aff><aff id="I3"><label>3</label>Queensland Children&#x02019;s Medical Research Institute, The University of Queensland, Brisbane, QLD, Australia</aff><aff id="I4"><label>4</label>Queensland Paediatric Infectious Diseases Laboratory, Royal Children&#x02019;s Hospital, Brisbane, QLD, Australia</aff><aff id="I5"><label>5</label>Department of Respiratory Medicine, Royal Children&#x02019;s Hospital, Murdoch Children&#x02019;s Research Institute, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="I6"><label>6</label>Department of Respiratory Medicine, Princess Margaret Hospital, Perth, Australia</aff><aff id="I7"><label>7</label>Department of Respiratory Medicine, The Children&#x02019;s Hospital at Westmead &#x00026; Sydney Medical School, University of Sydney, Sydney, NSW, Australia</aff><aff id="I8"><label>8</label>Royal Prince Alfred Hospital, Sydney, Australia</aff><aff id="I9"><label>9</label>Department of Paediatrics, University of Auckland and Starship Children&#x02019;s Hospital, Auckland, New Zealand</aff><aff id="I10"><label>10</label>Research and Education Support Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia</aff><aff id="I11"><label>11</label>Department of Paediatrics, Royal Darwin Hospital, Darwin, NT, Australia</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2012</year></pub-date><volume>13</volume><fpage>156</fpage><lpage>156</lpage><history><date date-type="received"><day>14</day><month>4</month><year>2012</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Chang et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Chang et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/13/1/156"/><abstract><sec><title>Background</title><p>Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis exacerbations, but not all practitioners agree. Inadequately treated exacerbations may risk lung function deterioration. Our study tests the hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of respiratory exacerbations by day 14 in children with bronchiectasis unrelated to cystic fibrosis.</p></sec><sec><title>Methods</title><p>We are conducting a <underline>b</underline>ronchiectasis <underline>e</underline>xacerbation <underline>st</underline>udy (BEST), which is a multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel group trial, in five centres (Brisbane, Perth, Darwin, Melbourne, Auckland). In the component of BEST presented here, 189 children fulfilling inclusion criteria are randomised (allocation-concealed) to receive amoxicillin-clavulanic acid (22.5&#x02009;mg/kg twice daily) with placebo-azithromycin; azithromycin (5&#x02009;mg/kg daily) with placebo-amoxicillin-clavulanic acid; or placebo-azithromycin with placebo-amoxicillin-clavulanic acid for 14&#x02009;days. Clinical data and a paediatric cough-specific quality of life score are obtained at baseline, at the start and resolution of exacerbations, and at day 14. In most children, blood and deep nasal swabs are also collected at the same time points. The primary outcome is the proportion of children whose exacerbations have resolved at day 14. The main secondary outcome is the paediatric cough-specific quality of life score. Other outcomes are time to next exacerbation; requirement for hospitalisation; duration of exacerbation; and spirometry data. Descriptive viral and bacteriological data from nasal samples and blood markers will also be reported.</p></sec><sec><title>Discussion</title><p>Effective, evidence-based management of exacerbations in people with bronchiectasis is clinically important. Yet, there are few randomised controlled trials (RCTs) in the neglected area of non-cystic fibrosis bronchiectasis. Indeed, no published RCTs addressing the treatment of bronchiectasis exacerbations in children exist. Our multicentre, double-blind RCT is designed to determine if azithromycin and amoxicillin-clavulanic acid, compared with placebo, improve symptom resolution on day 14 in children with acute respiratory exacerbations. Our planned assessment of the predictors of antibiotic response, the role of antibiotic-resistant respiratory pathogens, and whether early treatment with antibiotics affects duration and time to the next exacerbation, are also all novel.</p></sec><sec><title>Trial registration</title><p>Australia and New Zealand Clinical Trials Register (ANZCTR) number ACTRN12612000011886.</p></sec></abstract><kwd-group><kwd>Amoxicillin-clavulanic acid</kwd><kwd>Azithromycin</kwd><kwd>Bronchiectasis</kwd><kwd>Placebo</kwd><kwd>Pulmonary exacerbations</kwd><kwd>Randomised controlled trial</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Compared to the early 20th century, the prevalence of bronchiectasis has fallen substantially. Although regarded as an &#x02018;orphan disease&#x02019; in affluent countries, reports of prevalence of bronchiectasis are increasing [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Bronchiectasis remains a major contributor to chronic respiratory morbidity [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>] and mortality [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B4">4</xref>] in both Indigenous [<xref ref-type="bibr" rid="B5">5</xref>] and non-Indigenous populations [<xref ref-type="bibr" rid="B6">6</xref>]. In our recently completed multicentre study of children newly referred for chronic cough and managed in accordance to a standardised protocol [<xref ref-type="bibr" rid="B7">7</xref>], 31 (9%) of the 346 children had bronchiectasis proven on radiology [<xref ref-type="bibr" rid="B8">8</xref>]. In the Northern Territory in Australia, the incidence of bronchiectasis in the first year of life is 118 in 100,000 [<xref ref-type="bibr" rid="B9">9</xref>]. The estimated prevalence of bronchiectasis is 1,470 per 100,000 in Central Australian Indigenous children aged below 15&#x02009;years [<xref ref-type="bibr" rid="B10">10</xref>] and 1,600 per 100,000 in Alaskan Native children [<xref ref-type="bibr" rid="B11">11</xref>]. In the United States, reported prevalence in adults range from 4.2 to 271.8 per 100,000 [<xref ref-type="bibr" rid="B6">6</xref>]. However, any reported prevalence is likely to be an underestimate as many cases are misdiagnosed or coexist with other diseases like asthma [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>] and chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="B15">15</xref>]. Even without accounting for these unrecognised cases, globally there are far more patients with bronchiectasis than cystic fibrosis (CF), which has a prevalence of 7.4 to 7.9 per 100,000 in the European Union and the United States [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Effective clinical management reduces both short- and long-term morbidity (and likely mortality) associated with bronchiectasis [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. There is increasing evidence that intensive treatment of children who either have bronchiectasis or are at risk of developing severe bronchiectasis prevents poor lung function in adulthood [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Cohort data have shown that approximately 80% of newly diagnosed adults (non-smokers) with bronchiectasis reported symptoms dating back to childhood and that the duration of chronic cough (the most common symptom of bronchiectasis [<xref ref-type="bibr" rid="B21">21</xref>]) was related (r&#x02009;=&#x02009;&#x02212;0.51, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) to lung function at diagnosis [<xref ref-type="bibr" rid="B22">22</xref>]. Arguably, appropriate overall management and treatment of exacerbations (leading to reduction of persistent symptoms) potentially prevents or reduces deterioration of chronic respiratory disease [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Determinants of accelerated lung function decline in adults with bronchiectasis are the frequency of hospitalised exacerbations, increased systemic inflammatory markers and <italic>Pseudomonas aeruginosa</italic> infection [<xref ref-type="bibr" rid="B24">24</xref>]. Amongst other factors, increased mortality risk is associated with the degree of lung function impairment [<xref ref-type="bibr" rid="B25">25</xref>]. No prospective data exist in children. Our study and a London-based retrospective study found that, with appropriate treatment in specialised centres, lung function improves and can be maintained [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. However, those with poor lung function at diagnosis, although substantially improved, were likely to still have poor lung function five years later [<xref ref-type="bibr" rid="B20">20</xref>]. We also found that the only significant predictor of a decline in forced expiratory volume in one second (FEV<sub>1</sub>) was frequency of hospitalised exacerbations [<xref ref-type="bibr" rid="B20">20</xref>]. Forced expiratory volume in one second (FEV<sub>1</sub>)% predicted decreased by 1.95% with each previous hospitalised exacerbation [<xref ref-type="bibr" rid="B20">20</xref>]. As airway injury in children is superimposed upon the physiological changes involving lung growth and development [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>], improvement in childhood bronchiectasis may impact favourably upon future adult lung function. Early and effective management of bronchiectasis exacerbations in children may lead to reduced hospitalisations, better quality of life (QOL) and improved future adult lung function.</p><p>Antibiotics are one of the key interventions used to treat acute respiratory exacerbations of bronchiectasis [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. However, it is biologically plausible that antibiotics are not useful for treating some respiratory exacerbations triggered by viral infections. Our retrospective study found that 34% of exacerbations were preceded by a viral-like illness [<xref ref-type="bibr" rid="B29">29</xref>]. While most respiratory physicians will treat exacerbations intensively (with antibiotics and airway clearance), other doctors do not. Those choosing not to use antibiotics routinely argue that most episodes of exacerbations and cough are caused by viral infections and hence do not require antibiotic therapy. This may be appropriate but viral-bacterial interactions in the airways risk prolonged endobronchial bacterial infection that, with the associated inflammatory cascade, may cause further lung injury [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Better evidence to guide the management of exacerbations in people with bronchiectasis is needed.</p><sec><title>Aims of the study</title><p>There are two components of BEST; here we present the study protocol of the first phase (BEST-1). The second phase of BEST (BEST-2) will address the question &#x0201c;Is daily azithromycin non-inferior (within 20% margin) to amoxicillin-clavulanic acid in achieving resolution of exacerbations on day 21?&#x0201d; The protocol for BEST-2 will be the subject of a later paper.</p><p>This first phase of our proposed national multicentre double-blind double-dummy randomised controlled trial (RCT) is designed to answer our primary questions, as follows. Amongst children with non-CF bronchiectasis, does azithromycin improve the resolution of respiratory exacerbations by day 14 compared with placebo, and does amoxicillin-clavulanic acid improve the resolution of respiratory exacerbations by day 14 compared with placebo?</p><p>Our secondary aims are to:</p><p>1. determine the effect of azithromycin or amoxicillin-clavulanic acid on the QOL, systemic inflammation, time to next respiratory exacerbation, and duration of exacerbations;</p><p>2. explore factors that predict response to antibiotics, including respiratory pathogens (viruses, bacteria, macrolide-resistant bacteria) present in respiratory secretions and blood markers; and</p><p>3. describe the point prevalence and diversity of respiratory viruses, <italic>Mycoplasma pneumoniae</italic> and <italic>Chlamydia</italic> species during exacerbations using sensitive molecular detection techniques.</p><p>Our study tests the primary hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo in improving the resolution rate of respiratory exacerbations by day 14 in children with non-CF bronchiectasis.</p></sec></sec><sec><title>Methods/Design</title><sec><title>Study design</title><p>We are conducting a multicentre, parallel group, double-blind placebo RCT (with concealed allocation) to assess the impact of treatment with antibiotics (azithromycin or amoxicillin-clavulanic acid) in children with an exacerbation of bronchiectasis. Our study plan is summarised in Figure&#x02009;<xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Overall schematic study design.</bold> Amox-clav: amoxicillin-clavulanic acid; azithro: azithromycin.</p></caption><graphic xlink:href="1745-6215-13-156-1"/></fig></sec><sec><title>Eligibility</title><p>The inclusion criteria are age below 18&#x02009;years at time of study enrolment; diagnosed with bronchiectasis by a respiratory physician following high resolution computed tomography in the five years immediately prior to study entry or, if diagnosed earlier, have been followed regularly by a respiratory physician for treatment of bronchiectasis; and has experienced two or more respiratory exacerbations in the 18&#x02009;months prior to study entry.</p><p>Exclusion criteria are current severe exacerbation of bronchiectasis (dyspnoea, hypoxia or hospitalisation), recent (in last 8 weeks) in the entry; CF; liver dysfunction; allergy or sensitivity to penicillin or macrolides; current or recent lower airway infection by a member of the Pseudomonas genus group of Gram-negative bacteria (in the four months prior to study enrolment); has received antibiotics belonging to the macrolide or penicillin class of antibiotics within three weeks immediately prior to study entry; or is currently receiving oncological treatment.</p></sec><sec><title>Recruitment</title><p>Eligible children will be identified from clinics in our centres (Brisbane, Perth, Darwin and Melbourne in Australia and Auckland in New Zealand). Parents will be approached and informed consent obtained. Baseline pre-exacerbation data will be collected (Figure&#x02009;<xref ref-type="fig" rid="F1">1</xref>), parents contacted monthly and children reviewed every three months. Parents will be educated specifically on symptoms of exacerbations and asked to contact the research nurse at the onset of an exacerbation.</p></sec><sec><title>Intervention and follow-up</title><p>A double-dummy design is planned. If eligibility is fulfilled and after informed consent has been obtained, the child is randomised to one of three arms. At the start of the exacerbation, the child will receive amoxicillin-clavulanic acid with placebo-azithromycin, azithromycin with placebo-amoxicillin-clavulanic acid or placebo-azithromycin with placebo-amoxicillin-clavulanic acid. Amoxicillin-clavulanic acid dose is 22.5&#x02009;mg/kg/dose (up to 40&#x02009;kg) twice a day (max 900&#x02009;mg/dose). Azithromycin dose is 5&#x02009;mg/kg/day, max of 200&#x02009;mg daily. Equivalent volumes in placebo will be given in all arms. All treatments will continue for 14&#x02009;days.</p><p>An exacerbation is defined as an increase in sputum volume or purulence, or three or more days of change in cough (&#x0003e; 20% increase in cough score [<xref ref-type="bibr" rid="B31">31</xref>] or type (dry to wet) [<xref ref-type="bibr" rid="B32">32</xref>]). We validated this definition in our prospective study and found that the kappa values (between clinicians) of these symptoms and signs were excellent (&#x0003e; 0.75) [<xref ref-type="bibr" rid="B33">33</xref>]. Daily diaries will also be collected during exacerbations until the scores for two or more days reflect the child&#x02019;s &#x02018;baseline&#x02019; state, which for each child will be established at enrolment, prior to any exacerbations. This assessment consists of a combination of symptoms (daily cough (yes/no), cough quality (wet/dry/none) and cough score [<xref ref-type="bibr" rid="B31">31</xref>] averaged over two consecutive days) and signs (sputum colour (if any present) using a colour chart card (BronkoTest Ltd, London, UK), crackles on chest auscultation). Children will be reviewed on days 7 and 14 and at resolution of the exacerbation. The exacerbation is considered &#x02018;resolved&#x02019; when symptoms and signs are the same as &#x02018;baseline&#x02019; state. Post exacerbation, the children will be followed-up and clinically evaluated every three months for 18&#x02009;months or until their next exacerbation. &#x02018;Time to next exacerbation&#x02019; will be determined by the number of days from &#x02018;resolution of current exacerbation&#x02019; to beginning of the next exacerbation.</p></sec><sec><title>Randomisation, allocation and blinding</title><p>Upon enrolment, the child is assigned to the next unique number on the appropriate stratified list. The allocation will be performed by the trial pharmacist at the Royal Children&#x02019;s Hospital in Brisbane. Randomisation is stratified by site (Brisbane, Perth, Darwin, Melbourne, Auckland), age (&#x02264; 5 or&#x02009;&#x0003e;&#x02009;5&#x02009;years) and underlying aetiology (idiopathic/post-pneumonia or all other causes). The randomisation sequence was computer generated and used permuted blocks. The allocation sequence is concealed at all times throughout the study. The computer generated allocation sequence was prepared by a statistician external to the study team.</p><p>The placebo medications, specifically manufactured by the Institute of Drug Technology Australia Limited (Melbourne, Victoria), have a similar taste and colour to their respective antibiotics. Both active medications (amoxicillin-clavulanic acid and azithromycin) are repackaged by the Institute of Drug Technology. Thus both the amoxicillin-clavulanic acid and azithromycin and their respective placebos are in identical opaque bottles. For both types of trial medications, equal volumes of water are added using a syringe and needle by punching the seal. Adherence will be assessed by parent report and return of empty bottles.</p></sec><sec><title>Data collection</title><p>All data will be recorded on standardised forms. On enrolment, demographic information (age, gender, ethnicity, household size, and so on), birth history, breast feeding history, prior illness and in utero and household smoke exposure will be recorded, and a physical examination will be performed by a study physician. The primary and secondary outcome measures (see below) are collected at the time points specified above. Serious and non-serious adverse effects (nausea, vomiting, diarrhoea, rash) will also be documented and monitored. Safety exit points are discussed in End points below.</p></sec><sec><title>Specimen collection</title><p>At enrolment (baseline), all children will have a deep nasal swab (NS) specimen collected. In a subset, additional specimens will be collected at baseline and during exacerbations depending on feasibility (some children are unable to attend the study centre at the onset of the exacerbation) and willingness of parents to allow additional venipuncture. These specimens are:</p><p>A deep NS specimen for respiratory viruses, respiratory bacterial pathogens (with antibiotic susceptibility testing) and other potentially important respiratory pathogens (<italic>M. pneumoniae, Chlamydia</italic> spp) at baseline and at the beginning and resolution of an exacerbation. The technique used is identical to previous studies [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B36">36</xref>] where the specimens were described as nasopharyngeal swabs. The NSs are handled as per our research laboratory protocol (see below).</p><p>Bloods at baseline and at the beginning and end of each exacerbation for C-reactive protein (CRP), neutrophilic marker of inflammation (IL-6) [<xref ref-type="bibr" rid="B37">37</xref>], serum amyloid A (SAA) [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B38">38</xref>] and markers of viral infection (interferon gamma-inducible protein 10 (IP-10) and IL-10).</p><p>Sputum at baseline and at the beginning and end of each exacerbation (when possible) for lower airway microbiology and antibiotic sensitivity.</p></sec><sec><title>Further description of scores and laboratory methods</title><sec><title>Cough score</title><p>The verbal categorical descriptive score is a validated daily diary score of cough rated on a six-point scale (0&#x02009;=&#x02009;no cough to 5&#x02009;=&#x02009;severe cough and cannot perform activities) with increasing scores reflecting greater interference with usual activities. This rating was validated against an objective cough meter measure [<xref ref-type="bibr" rid="B31">31</xref>] and changes in cough scores have been shown to reflect changes in objective cough counts [<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Parent Chronic Cough Quality of Life score</title><p>The Parent Chronic Cough Quality of Life (PC-QOL) is a 27-item questionnaire designed to assess the level of frequency of feelings (15 items) and worry (12 items) related to their child&#x02019;s cough. It uses a seven-point Likert-type scale with higher scores reflecting less frequency and fewer worry concerns (that is, greater QOL) [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. The minimal important difference is 0.62 determined by the distribution method and 0.9 determined by the anchor method [<xref ref-type="bibr" rid="B42">42</xref>].</p></sec><sec><title>Bacteriology of nasal swabs</title><p>Oropharyngeal sampling under estimates <italic>Streptococcus pneumoniae</italic> carriage by approximately 50% when compared with NS [<xref ref-type="bibr" rid="B43">43</xref>]. Thus, NS are the preferred method when evaluating the presence of antibiotic-resistant bacteria. Culturing, identifying and, when appropriate, serotyping common respiratory bacteria are established techniques at our research laboratory [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Swabs are stored in skim milk tryptone glucose glycerol broth medium at &#x02212;80&#x000b0;C before being batch processed for typical respiratory bacterial pathogens, notably <italic>Haemophilus influenzae (</italic>including strains of non-typeable <italic>H. influenzae)</italic>, <italic>Moraxella catarrhalis</italic> and <italic>S. pneumoniae</italic>. Batches of swabs are thawed and 10-&#x003bc;L aliquots cultured overnight on selective media at 37&#x000b0;C in 5% carbon dioxide. Growth of <italic>S. pneumoniae</italic>, <italic>H. influenzae</italic> and <italic>M. catarrhalis</italic> is recorded and confirmed by standard techniques [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. Four isolates each of <italic>S. pneumoniae</italic> and <italic>H. influenzae</italic> and two isolates of <italic>M. catarrhalis</italic> per positive swab are tested for antimicrobial resistance and stored [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. <italic>S. pneumoniae</italic> isolates are serotyped using the Quellung method (antisera from Statens Serum Institute, Copenhagen,Denmark).</p><p>In addition to routine susceptibility testing using the calibrated dichotomous susceptibility disc diffusion method, azithromycin minimum inhibitory concentration (MIC) will be determined by Etests (AB Biodisk, Solna, Sweden) if the azithromycin disc annulus is &#x0003c;6&#x02009;mm. For <italic>S. pneumoniae</italic>, the penicillin MIC is determined for penicillin non-susceptible isolates (oxacillin and/or penicillin disc annulus&#x02009;&#x0003c;&#x02009;6&#x02009;mm) and for <italic>H. influenzae</italic>, the ampicillin MIC is determined for isolates if the ampicillin disc annulus is&#x02009;&#x0003c;&#x02009;6&#x02009;mm. Interpretive criteria (Clinical and Laboratory Standards Institute breakpoints) used for <italic>S. pneumoniae</italic> are penicillin non-susceptible MIC&#x02009;&#x0003e;&#x02009;0.12&#x02009;&#x003bc;g/mL, azithromycin resistance MIC&#x02009;&#x02265;&#x02009;2&#x02009;&#x003bc;g/mL; and for <italic>H. influenzae</italic>, ampicillin resistance MIC&#x02009;&#x02265;&#x02009;4&#x02009;&#x003bc;g/mL, azithromycin resistance MIC&#x02009;&#x0003e;&#x02009;4&#x02009;&#x003bc;g/mL. A nitrocephin-based test will identify beta-lactamase activity in <italic>H. influenzae</italic> and <italic>M. catarrhalis</italic> isolates.</p></sec><sec><title>Assessment for viruses and atypical bacteria</title><p>We will use our previous methods [<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>]. Nucleic acids will be extracted from the media using the High Pure Viral Nucleic Acid kit (Roche Diagnostics, Sydney, New South Wales, Australia), according to the manufacturer&#x02019;s instructions. Real-time polymerase chain reaction assays will be used to detect respiratory syncytial viruses (A and B), adenoviruses, influenza viruses (A and B), parainfluenza, human metapneumovirus, human coronaviruses (OC43, HK1, 229E, NL63), enteroviruses, rhinoviruses (and subtypes [<xref ref-type="bibr" rid="B48">48</xref>]) and the more recently described human viruses (human bocavirus 1, parechoviruses, human polyomaviruses K1 and WU) and <italic>M. pneumoniae</italic> and <italic>Chlamydia</italic> species [<xref ref-type="bibr" rid="B49">49</xref>].</p></sec><sec><title>Blood markers</title><p>Serum CRP (threshold 5&#x02009;mg/L) are standard tests that will be analysed locally (diagnostic laboratory of each participating centre). SAA, IL-6 (threshold&#x02009;&#x0003c;&#x02009;3&#x02009;pg/mL), IL-10 (threshold&#x02009;&#x0003c;&#x02009;0.5&#x02009;pg/mL) and IP-10 (threshold 2.8&#x02009;pg/mL) will be performed using ELISA commercial kits (R&#x00026;D Systems, Minneapolis, MN, USA) at our research laboratory.</p></sec><sec><title>Spirometry</title><p>Spirometry (in children aged&#x02009;&#x02265;&#x02009;5&#x02009;years) will be performed using American Thoracic Society criteria and the FEV<sub>1</sub>% predicted recorded. We elected not to use oscillatory measures as we found no difference in airway resistance between steady and exacerbation states [<xref ref-type="bibr" rid="B33">33</xref>]. Thus we will use conventional spirometry although we do not expect to detect significant differences.</p></sec></sec><sec><title>End points</title><p>Participation is complete when the child&#x02019;s clinical state returns to baseline and the &#x02018;time to next exacerbation&#x02019; has been obtained. Other exit points are if the child is clinically worse prior to day 14 or intolerance to the trial medications requiring withdrawal from the study (as determined by the treating clinician).</p></sec><sec><title>Outcome measures</title><sec><title>Primary outcome</title><p>The primary outcome is the proportion of children whose exacerbations have resolved by day 14. Exacerbations will be considered resolved when symptoms and signs are the same as the baseline state. Children who are withdrawn from the study or receive additional antibiotic treatment will be categorised as non-resolved.</p></sec><sec><title>Secondary clinical outcomes</title><p>The main secondary outcome is the PC-QOL score. Other outcomes are the time to next exacerbation; requirement for hospitalisation; duration of exacerbation (persistence of symptoms till &#x02018;return to baseline state&#x02019;) and FEV<sub>1</sub>% predicted.</p></sec><sec><title>Secondary laboratory outcomes</title><p>Serum markers (CRP, SAA, IL-6, IL-10, IP-10) and data on viruses and respiratory bacterial pathogens, including antibiotic susceptibility patterns to penicillin and azithromycin, will be the secondary laboratory outcomes.</p></sec></sec><sec><title>Sample size</title><p>We plan to enrol 189 children (63 per arm), providing 84% power (&#x003b1;&#x02009;=&#x02009;0.0245, two-sided) to detect a halving of the number of children in the active arm achieving resolution by day 14 (that is, azithromycin or amoxicillin-clavulanic acid: 60% resolved by day 14, compared with placebo: 30% resolved). This is a conservative estimate when compared with our prospective data of persistent symptoms in 24% of children based on the same diary card [<xref ref-type="bibr" rid="B50">50</xref>]. As the primary outcome will be obtained in all enrolled children, a drop-out has not been factored in for the intention-to-treat analysis. With 20% drop-out rate, data from 153 children (51 per arm) for &#x02018;per protocol&#x02019; analysis provides a study power of 75%. Both treatment arms are compared with the same placebo arm. While the maximum efficiency is attained by allocating more children to the placebo arm (that is, using an allocation ratio of 1:1:&#x0221a;2), we chose to use a 1:1:1 allocation due to ethical concerns of deviating from standard care in respiratory centres.</p><p>In the main secondary outcome (PC-QOL), based on a between-group difference of 0.9 (minimum important difference [<xref ref-type="bibr" rid="B42">42</xref>]) (SD 0.9), our sample size provides power of 100% (&#x003b1;&#x02009;=&#x02009;0.05) for data from at least 147 children (that is, assuming at least 80% retention of the 189 children enrolled). For secondary aim 2 (exploring factors that predict response to antibiotics), we will be examining eight main factors and thus a sample size of 147 exceeds the recommended minimum (n&#x02009;=&#x02009;10 per factor) [<xref ref-type="bibr" rid="B51">51</xref>]. The eight factors are smoking, age, underlying aetiology, detection of virus (any versus none, then single versus multiple viruses), presence of azithromycin resistance and blood markers (IL-6, IL-10, IP-10 levels).</p></sec><sec><title>Statistical analysis and reporting</title><p>Data will be reported and presented in accordance with the updated CONSORT criteria [<xref ref-type="bibr" rid="B52">52</xref>]. Children will be analysed according to allocation status (regardless of subsequent management). An interim analysis is planned and a data safety and monitoring committee will determine if the study should be ceased should superiority of any antibiotic be identified after 50% of sample size is achieved.</p><p>For our primary aim, the main effects of the interventions will be determined by comparing the primary outcome (resolution of exacerbation) between groups ((azithromycin versus placebo) and (amoxicillin-clavulanic acid versus placebo)). Children who exit the study as clinically worse or drop-outs prior to the end point will be considered non-resolved. Those who exit the study as &#x02018;returned to baseline&#x02019; will be considered resolved. Odds ratios will be calculated and, if appropriate, number needed to treat (for benefit) will be expressed. Tests of a treatment arm versus placebo at the end of the study for the primary outcome will be performed at the 2.45% significance level to account for spending some alpha at the interim analysis. Per protocol analysis will be an <italic>a priori</italic> secondary analysis.</p><sec><title>For secondary outcomes and aims</title><p>For clinical secondary outcomes (secondary aim 1), t-tests or Mann&#x02013;Whitney will be used for continuous variables (according to normality of data distribution). A Kaplan-Meier curve will be constructed for each group for &#x02018;time to resolution&#x02019; and &#x02018;time to next exacerbation&#x02019; as done previously [<xref ref-type="bibr" rid="B53">53</xref>]. For secondary aim 2 (factors that predict response to antibiotics), univariate analysis will be used to examine the biological factors listed above. Factors that have a <italic>P-</italic>value&#x02009;&#x0003c;&#x02009;0.2 will be included in a logistic regression model. Potential interactions (for example, virus with bacteria) will be examined in the model. Descriptive data will be used for secondary aim 3 (point prevalence of respiratory pathogens).</p></sec></sec><sec><title>Data safety monitoring committee</title><p>A data safety monitoring committee has been established and has met prior to commencement of this study. It was determined that, when 50% of the sample size has been achieved, the stopping rules are as detailed below.</p><p>If superiority between each antibiotic arm and the placebo arm is shown at significance level of 0.001, the study will cease. If superiority of only one antibiotic is shown, we will continue recruiting children to the other antibiotic arm and to the placebo arm but not to the superior antibiotic arm.</p><p>If the serious adverse events (related to the medications) in each antibiotic arm outnumber the adverse events in the placebo arm at significance level of 0.01 or less, the study will cease. If increased adverse events of only one antibiotic is shown, we will continue recruiting children to the other antibiotic arm and to the placebo arm but not to the antibiotic arm related with increased adverse events. However, the study is not powered to detect between-group differences in total adverse events.</p></sec><sec><title>Ethics approval</title><p>The protocol has received ethical approval from the respective Human Research Ethics Committees of all the participating institutions (Darwin: Department of Health and Families and Menzies School of Health Research; Brisbane: Children&#x02019;s Health Services (Royal Children&#x02019;s Hospital) and University of Queensland; Perth: Princess Margaret Hospital; Melbourne: Royal Children&#x02019;s Hospital; Auckland: Northern Ethics Committee, Ministry of Health and Starship Children&#x02019;s Health local ethics committee). The study is being conducted under Australia&#x02019;s Therapeutic Goods Administration Clinical Trial Notification scheme.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Despite the considerable global burden, bronchiectasis services receive disproportionately fewer allocated resources (clinical and research) when compared with other chronic respiratory diseases [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. The marked paucity of RCTs [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B55">55</xref>] is reflected in the existence of only a single (small) published placebo-controlled RCT in children with bronchiectasis [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B56">56</xref>]. That study described a reduction in sputum purulence and airway hyper-responsiveness in children receiving roxithromycin (n&#x02009;=&#x02009;13) [<xref ref-type="bibr" rid="B57">57</xref>]. There are no RCTs on the management of bronchiectasis exacerbations in children [<xref ref-type="bibr" rid="B58">58</xref>]. Almost all current recommendations are based on CF management [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Such extrapolation can, on occasions, be detrimental for those with non-CF bronchiectasis. For example, a large RCT found that deoxyribonuclease (efficacious for CF) increased exacerbations and decline in FEV<sub>1</sub> in adults with bronchiectasis [<xref ref-type="bibr" rid="B59">59</xref>] despite prior case reports advocating its use [<xref ref-type="bibr" rid="B60">60</xref>].</p><p>The importance of exacerbations in most chronic respiratory diseases is generally accepted. Unfortunately, data on triggers, definitions and effective treatment of bronchiectasis exacerbations in both children and adults are scarce [<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B61">61</xref>,<xref ref-type="bibr" rid="B62">62</xref>]. Although viral triggers of acute exacerbations are well described in asthma [<xref ref-type="bibr" rid="B46">46</xref>] and COPD [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>], no such data exist for bronchiectasis. Whether other potential respiratory pathogens (<italic>M. pneumoniae</italic> and <italic>Chlamydia</italic> species) trigger exacerbations has never been examined. Our retrospective study found that 34% of exacerbations were preceded by a viral-like illness [<xref ref-type="bibr" rid="B29">29</xref>]. Thus, for the first time in this population, we will determine the nature and diversity of respiratory viruses <italic>M. pneumoniae</italic> and <italic>Chlamydia</italic> species associated with bronchiectasis exacerbations.</p><p>Our study addresses a large knowledge gap in an under-researched area [<xref ref-type="bibr" rid="B55">55</xref>]. If the intervention is successful, it would lead to improved short-term (and possibly long-term) health benefits. Conclusive results would produce changes to evidence-based standard treatment guidelines.</p><sec><title>The rationale for our chosen outcome measures and timeframe</title><p>In our retrospective data of 115 respiratory exacerbations [<xref ref-type="bibr" rid="B29">29</xref>], we found that 35% of exacerbations failed to respond to oral antibiotic therapy (duration could not be determined) and required hospital admission. In our prospective cohort of 69 children followed for 900 child-months (156 exacerbations), 36 exacerbations (23%) were treated with intravenous antibiotics following persistence of symptoms, that is, non-resolution of the exacerbation episode. Generally, hospitalisation began three to five weeks following the initiation of oral antibiotics and &#x02018;return to baseline&#x02019; occurred within two weeks of hospitalisation. Based on our data that 24% of otherwise well children in the community still have a cough associated with a viral infection at day 14 [<xref ref-type="bibr" rid="B50">50</xref>], we chose day 14 as the time point for this RCT. We also asked parents and clinicians about their willingness to use placebo for a period of time; 14&#x02009;days was the limit with a safety exit point at day 7.</p><p>Adult bronchiectasis studies show that QOL measures, particularly cough-specific QOL, are valid and important outcome measures [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B65">65</xref>]. Likewise, we have shown the utility of a paediatric chronic cough QOL (the PC-QOL) score in children with bronchiectasis [<xref ref-type="bibr" rid="B66">66</xref>].</p><p>In summary, our double-blind, double-dummy RCT that examines the superiority of azithromycin and amoxicillin-clavulanic acid (compared with placebo) for exacerbations of bronchiectasis in children has the potential to have both short-term gains and a long-term benefit for reducing the morbidity of bronchiectasis.</p></sec></sec><sec><title>Trial status</title><p>We commenced recruitment in Darwin in mid-March 2012, Brisbane in June 2012 and the other sites are expected to commence in August 2012. We commenced randomisation in late May 2012.</p></sec><sec><title>Abbreviations</title><p>BEST: Bronchiectasis Exacerbation Study; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ELISA: enzyme-linked immunosorbent assay; FEV<sub>1</sub>: forced expiratory volume in one second; IL: interleukin; IP-10: interferon gamma-inducible protein 10; MIC: minimum inhibitory concentration; NS: nasal swab; PC-QOL: parent chronic cough quality of life; QOL: Quality of life; RCT: randomised controlled trial; SAA: serum amyloid A; SD: standard deviation.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>AC conceived the study, and participated in its design and coordination and drafted the manuscript. PM, CR, KG, PvA, AW, KO, PT and TS participated in its design and submission to the National Health and Medical Research Council. EB and GM participated in initiating the project and IMM in the viral analysis plan. IBM, CB and HB will assist in recruitment and assessment of the children. MDC advised on statistical issues. All authors read and approved the final manuscript.</p></sec><sec><title>Authors&#x02019; information</title><p>ABC, CFR, ACW, PPvA, CAB, IBM and HMB are paediatric respiratory physicians, KG is a paediatric infectious disease physician, PJT is an adult respiratory physician, KFO is an epidemiologist, TPS and IMM are virologists, MDC is a statistician, EJB and GBM are research nurses and PM is a general paediatrician.</p></sec></body><back><sec><title>Acknowledgements</title><p>We thank the research staff (Lesley Versteegh, Clare Wilson, Sophie Anderson-James, Joanne Tuppin, Stacey Spencer, Carol Willis) for facilitating the study, Robert Ware for generating the randomisation sequences and Anita Champion for allocating the children and dispensing the medications. We are also grateful to members of the Indigenous Reference Group of the Child Health Division at Menzies for supporting this study and for overseeing the cultural aspects. We also thank Professor Alan Isles, Professor Craig Mellis and Associate Professor Chris Blyth for voluntarily providing their time in their participation as members of the data safety monitoring committee.</p><p>The study is funded by a three-year National Health and Medical Research Council (NHMRC) project grant (number 1019834) and supported by a NHMRC Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children grant (number 1040830). AC (grant 545216) is supported by a NHMRC practitioner fellowship. KO is supported by Queensland Children&#x02019;s Medical Research Institute and Queensland Government Smart Futures fellowships. The views expressed in this publication are those of the authors and do not reflect the views of NHMRC.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>HJ</given-names></name><name><surname>Hubbard</surname><given-names>R</given-names></name><article-title>Trends in bronchiectasis mortality in England and Wales</article-title><source>Respir Med</source><year>2010</year><volume>104</volume><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2010.02.022</pub-id><pub-id pub-id-type="pmid">20303725</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Seitz</surname><given-names>AE</given-names></name><name><surname>Olivier</surname><given-names>KN</given-names></name><name><surname>Steiner</surname><given-names>CA</given-names></name><name><surname>De Oca</surname><given-names>RM</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Prevots</surname><given-names>DR</given-names></name><article-title>Trends and burden of bronchiectasis-associated hospitalizations: USA, 1993&#x02013;2006</article-title><source>Chest</source><year>2010</year><volume>138</volume><fpage>944</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1378/chest.10-0099</pub-id><pub-id pub-id-type="pmid">20435655</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Santamaria</surname><given-names>F</given-names></name><name><surname>Montella</surname><given-names>S</given-names></name><name><surname>Pifferi</surname><given-names>M</given-names></name><name><surname>Ragazzo</surname><given-names>V</given-names></name><name><surname>De</surname><given-names>SS</given-names></name><name><surname>De</surname><given-names>PN</given-names></name><name><surname>Maglione</surname><given-names>M</given-names></name><name><surname>Boner</surname><given-names>AL</given-names></name><article-title>A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy</article-title><source>Respiration</source><year>2009</year><volume>77</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1159/000137510</pub-id><pub-id pub-id-type="pmid">18523381</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Steinfort</surname><given-names>DP</given-names></name><name><surname>Brady</surname><given-names>S</given-names></name><name><surname>Weisinger</surname><given-names>HS</given-names></name><name><surname>Einsiedel</surname><given-names>L</given-names></name><article-title>Bronchiectasis in Central Australia: a young face to an old disease</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2007.11.007</pub-id><pub-id pub-id-type="pmid">18086522</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name><name><surname>Macguire</surname><given-names>G</given-names></name><name><surname>King</surname><given-names>PT</given-names></name><name><surname>Morris</surname><given-names>PS</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><article-title>Management of bronchiectasis and chronic suppurative lung disease (CSLD) in Indigenous children and adults from rural and remote Australian communities</article-title><source>Med J Aust</source><year>2008</year><volume>189</volume><fpage>386</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">18837683</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Weycker</surname><given-names>D</given-names></name><name><surname>Edelsberg</surname><given-names>J</given-names></name><name><surname>Oster</surname><given-names>G</given-names></name><name><surname>Tino</surname><given-names>G</given-names></name><article-title>Prevalence and economic burden of bronchiectasis</article-title><source>Clin Pulm Med</source><year>2005</year><volume>12</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1097/01.cpm.0000171422.98696.ed</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><name><surname>van Asperen</surname><given-names>PP</given-names></name><name><surname>Glasgow</surname><given-names>NJ</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Mellis</surname><given-names>CM</given-names></name><name><surname>Landau</surname><given-names>LI</given-names></name><name><surname>Teoh</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>PS</given-names></name><article-title>Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-103</pub-id><pub-id pub-id-type="pmid">21054884</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="other"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><name><surname>van Asperen</surname><given-names>PP</given-names></name><name><surname>Glasgow</surname><given-names>NJ</given-names></name><name><surname>Mellis</surname><given-names>CM</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Teoh</surname><given-names>L</given-names></name><name><surname>Tjhung</surname><given-names>I</given-names></name><name><surname>Morris</surname><given-names>PS</given-names></name><name><surname>Petsky</surname><given-names>HL</given-names></name><name><surname>Willis</surname><given-names>C</given-names></name><name><surname>Landau</surname><given-names>LI</given-names></name><article-title>A multi-centre study on chronic cough in children: burden and etiologies based on a standardized management pathway</article-title><source>Chest</source><year>2012</year><comment>Epub ahead of print</comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>O'Grady</surname><given-names>KA</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life</article-title><source>Med J Aust</source><year>2010</year><volume>192</volume><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">20477735</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Masel</surname><given-names>JP</given-names></name><name><surname>Boyce</surname><given-names>NC</given-names></name><name><surname>Wheaton</surname><given-names>G</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><article-title>Non-CF bronchiectasis-clinical and HRCT evaluation</article-title><source>Pediatr Pulmonol</source><year>2003</year><volume>35</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1002/ppul.10289</pub-id><pub-id pub-id-type="pmid">12746947</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Singleton</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Redding</surname><given-names>G</given-names></name><name><surname>Poll</surname><given-names>J</given-names></name><name><surname>Holck</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Kruse</surname><given-names>D</given-names></name><name><surname>Bulkow</surname><given-names>LR</given-names></name><name><surname>Petersen</surname><given-names>KM</given-names></name><name><surname>Lewis</surname><given-names>C</given-names></name><article-title>Bronchiectasis in Alaska Native children: causes and clinical courses</article-title><source>Pediatr Pulmonol</source><year>2000</year><volume>29</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-0496(200003)29:3&#x0003c;182::AID-PPUL5&#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">10686038</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Donnelly</surname><given-names>DE</given-names></name><name><surname>Critchlow</surname><given-names>A</given-names></name><name><surname>Everard</surname><given-names>ML</given-names></name><article-title>Outcomes in children treated for persistent bacterial bronchitis</article-title><source>Thorax</source><year>2007</year><volume>62</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1136/thx.2006.058933</pub-id><pub-id pub-id-type="pmid">17105776</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Haldar</surname><given-names>P</given-names></name><name><surname>Raj</surname><given-names>JV</given-names></name><name><surname>Entwisle</surname><given-names>JJ</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Green</surname><given-names>RH</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><article-title>Qualitative analysis of high resolution computed tomography scans in severe asthma</article-title><source>Chest</source><year>2009</year><volume>136</volume><fpage>1521</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1378/chest.09-0174</pub-id><pub-id pub-id-type="pmid">19542254</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Farrell</surname><given-names>PM</given-names></name><article-title>The prevalence of cystic fibrosis in the European Union</article-title><source>J Cyst Fibros</source><year>2008</year><volume>7</volume><fpage>450</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2008.03.007</pub-id><pub-id pub-id-type="pmid">18442953</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>O'Brien</surname><given-names>C</given-names></name><name><surname>Guest</surname><given-names>PJ</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name><article-title>Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care</article-title><source>Thorax</source><year>2000</year><volume>55</volume><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1136/thorax.55.8.635</pub-id><pub-id pub-id-type="pmid">10899238</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Dogru</surname><given-names>D</given-names></name><name><surname>Nik-Ain</surname><given-names>A</given-names></name><name><surname>Kiper</surname><given-names>N</given-names></name><name><surname>Gocmen</surname><given-names>A</given-names></name><name><surname>Ozcelik</surname><given-names>U</given-names></name><name><surname>Yalcin</surname><given-names>E</given-names></name><name><surname>Aslan</surname><given-names>AT</given-names></name><article-title>Bronchiectasis: the consequence of late diagnosis in chronic respiratory symptoms</article-title><source>J Trop Pediatr</source><year>2005</year><volume>51</volume><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/tropej/fmi036</pub-id><pub-id pub-id-type="pmid">15890722</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Haidopoulou</surname><given-names>K</given-names></name><name><surname>Calder</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Jaffe</surname><given-names>A</given-names></name><name><surname>Sonnappa</surname><given-names>S</given-names></name><article-title>Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function</article-title><source>Pediatr Pulmonol</source><year>2009</year><volume>44</volume><fpage>669</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1002/ppul.21036</pub-id><pub-id pub-id-type="pmid">19514055</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Bastardo</surname><given-names>CM</given-names></name><name><surname>Sonnappa</surname><given-names>S</given-names></name><name><surname>Stanojevic</surname><given-names>S</given-names></name><name><surname>Navarro</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>PM</given-names></name><name><surname>Jaffe</surname><given-names>A</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><article-title>Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function</article-title><source>Thorax</source><year>2009</year><volume>64</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1136/thx.2008.100958</pub-id><pub-id pub-id-type="pmid">19052050</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Ellerman</surname><given-names>A</given-names></name><name><surname>Bisgaard</surname><given-names>H</given-names></name><article-title>Longitudinal study of lung function in a cohort of primary ciliary dyskinesia</article-title><source>Eur Respir J</source><year>1997</year><volume>10</volume><fpage>2376</fpage><lpage>2379</lpage><pub-id pub-id-type="doi">10.1183/09031936.97.10102376</pub-id><pub-id pub-id-type="pmid">9387968</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability?</article-title><source>Chest</source><year>2010</year><volume>138</volume><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1378/chest.10424</pub-id><pub-id pub-id-type="pmid">20173055</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Bell</surname><given-names>SC</given-names></name><name><surname>Byrnes</surname><given-names>CA</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name><name><surname>Holmes</surname><given-names>PW</given-names></name><name><surname>King</surname><given-names>PT</given-names></name><name><surname>Kolbe</surname><given-names>J</given-names></name><name><surname>Landau</surname><given-names>LI</given-names></name><name><surname>Maguire</surname><given-names>GP</given-names></name><name><surname>McDonald</surname><given-names>MI</given-names></name><name><surname>Reid</surname><given-names>DW</given-names></name><name><surname>Thien</surname><given-names>FC</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><article-title>Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: Thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement</article-title><source>Med J Aust</source><year>2010</year><volume>193</volume><fpage>356</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">20854242</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>King</surname><given-names>PT</given-names></name><name><surname>Holdsworth</surname><given-names>SR</given-names></name><name><surname>Farmer</surname><given-names>M</given-names></name><name><surname>Freezer</surname><given-names>N</given-names></name><name><surname>Villanueva</surname><given-names>E</given-names></name><name><surname>Holmes</surname><given-names>PW</given-names></name><article-title>Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood</article-title><source>COPD</source><year>2009</year><volume>6</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1080/15412550902766934</pub-id><pub-id pub-id-type="pmid">19378226</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Byrnes</surname><given-names>CA</given-names></name><name><surname>Everard</surname><given-names>ML</given-names></name><article-title>Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis</article-title><source>Paediatr Respir Rev</source><year>2011</year><volume>12</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.prrv.2010.10.008</pub-id><pub-id pub-id-type="pmid">21458737</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name><name><surname>Soler-Cataluna</surname><given-names>JJ</given-names></name><name><surname>Perpina-Tordera</surname><given-names>M</given-names></name><name><surname>Roman-Sanchez</surname><given-names>P</given-names></name><name><surname>Soriano</surname><given-names>J</given-names></name><article-title>Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>1565</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1378/chest.07-0490</pub-id><pub-id pub-id-type="pmid">17998359</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Loebinger</surname><given-names>MR</given-names></name><name><surname>Wells</surname><given-names>AU</given-names></name><name><surname>Hansell</surname><given-names>DM</given-names></name><name><surname>Chinyanganya</surname><given-names>N</given-names></name><name><surname>Devaraj</surname><given-names>A</given-names></name><name><surname>Meister</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><article-title>Mortality in bronchiectasis: a long-term study assessing the factors influencing survival</article-title><source>Eur Respir J</source><year>2009</year><volume>34</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1183/09031936.00003709</pub-id><pub-id pub-id-type="pmid">19357155</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Pediatric cough: children are not miniature adults</article-title><source>Lung</source><year>2010</year><volume>188</volume><fpage>S33</fpage><lpage>S40</lpage><pub-id pub-id-type="pmid">19672656</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Redding</surname><given-names>GJ</given-names></name><name><surname>Everard</surname><given-names>ML</given-names></name><article-title>State of the art - chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis</article-title><source>Pediatr Pulmonol</source><year>2008</year><volume>43</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1002/ppul.20821</pub-id><pub-id pub-id-type="pmid">18435475</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Pasteur</surname><given-names>MC</given-names></name><name><surname>Bilton</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name><article-title>British Thoracic Society guideline for non-CF bronchiectasis</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>i1</fpage><lpage>i58</lpage><pub-id pub-id-type="doi">10.1136/thx.2010.136119</pub-id><pub-id pub-id-type="pmid">20627931</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations</article-title><source>Respir Med</source><year>2009</year><volume>103</volume><fpage>1681</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2009.05.007</pub-id><pub-id pub-id-type="pmid">19501498</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>PJ</given-names></name><article-title>Inflammation: a two edged sword. The model of bronchiectasis</article-title><source>Eur J Respir Dis</source><year>1986</year><volume>147</volume><fpage>6</fpage><lpage>15</lpage></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Newman</surname><given-names>RG</given-names></name><name><surname>Carlin</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>PD</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><article-title>Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method</article-title><source>Eur Respir J</source><year>1998</year><volume>11</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1183/09031936.98.11020462</pub-id><pub-id pub-id-type="pmid">9551755</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Eastburn</surname><given-names>MM</given-names></name><name><surname>Gaffney</surname><given-names>J</given-names></name><name><surname>Faoagali</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>NC</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><article-title>Cough quality in children: a comparison of subjective vs. bronchoscopic findings</article-title><source>Respir Res</source><year>2005</year><volume>6</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-6-3</pub-id><pub-id pub-id-type="pmid">15638942</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Morris</surname><given-names>PS</given-names></name><name><surname>Galligan</surname><given-names>J</given-names></name><name><surname>Ware</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis</article-title><source>Pediatr Pulmonol</source><year>2012</year><volume>47</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/ppul.21518</pub-id><pub-id pub-id-type="pmid">21830316</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Leach</surname><given-names>AJ</given-names></name><name><surname>Boswell</surname><given-names>JB</given-names></name><name><surname>Asche</surname><given-names>V</given-names></name><name><surname>Nienhuys</surname><given-names>TG</given-names></name><name><surname>Mathews</surname><given-names>JD</given-names></name><article-title>Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants</article-title><source>Pediatr Infect Dis J</source><year>1994</year><volume>13</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1097/00006454-199411000-00009</pub-id><pub-id pub-id-type="pmid">7845752</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>AV</given-names></name><name><surname>Maclennan</surname><given-names>C</given-names></name><name><surname>Sloots</surname><given-names>TP</given-names></name><name><surname>Sive</surname><given-names>A</given-names></name><name><surname>McCallum</surname><given-names>GB</given-names></name><name><surname>Mackay</surname><given-names>IM</given-names></name><name><surname>Morris</surname><given-names>PS</given-names></name><article-title>Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol</article-title><source>Trials</source><year>2011</year><volume>12</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-12-94</pub-id><pub-id pub-id-type="pmid">21492416</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Hare</surname><given-names>KM</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name><name><surname>Leach</surname><given-names>AJ</given-names></name><name><surname>Smith-Vaughan</surname><given-names>HC</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><name><surname>Morris</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.06.002</pub-id><pub-id pub-id-type="pmid">20656297</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>LG</given-names></name><name><surname>Scott</surname><given-names>HA</given-names></name><name><surname>Garg</surname><given-names>ML</given-names></name><name><surname>Gibson</surname><given-names>PG</given-names></name><article-title>Innate immune mechanisms linking non-esterified fatty acids and respiratory disease</article-title><source>Prog Lipid Res</source><year>2009</year><volume>48</volume><fpage>27</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2008.10.001</pub-id><pub-id pub-id-type="pmid">19017534</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name><name><surname>Perpina-Tordera</surname><given-names>M</given-names></name><name><surname>Roman-Sanchez</surname><given-names>P</given-names></name><name><surname>Soler-Cataluna</surname><given-names>JJ</given-names></name><article-title>Quality-of-life determinants in patients with clinically stable bronchiectasis</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>739</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1378/chest.128.2.739</pub-id><pub-id pub-id-type="pmid">16100162</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Phelan</surname><given-names>PD</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><name><surname>Roberts</surname><given-names>RDG</given-names></name><name><surname>Sawyer</surname><given-names>SM</given-names></name><article-title>Relationship between measurements of cough severity</article-title><source>Arch Dis Child</source><year>2003</year><volume>88</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1136/adc.88.1.57</pub-id><pub-id pub-id-type="pmid">12495964</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Newcombe</surname><given-names>PA</given-names></name><name><surname>Sheffield</surname><given-names>JK</given-names></name><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Halstead</surname><given-names>RA</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Development of a parent-proxy quality-of-life chronic cough-specific questionnaire: clinical impact vs psychometric evaluations</article-title><source>Chest</source><year>2008</year><volume>133</volume><fpage>386</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1378/chest.07-0888</pub-id><pub-id pub-id-type="pmid">18252913</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Newcombe</surname><given-names>PA</given-names></name><name><surname>Sheffield</surname><given-names>JK</given-names></name><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Petsky</surname><given-names>HL</given-names></name><name><surname>Willis</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Validation of a parent-proxy quality-of-life questionnaire (PC-QOL) for paediatric chronic cough</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1136/thx.2009.133868</pub-id><pub-id pub-id-type="pmid">20805179</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Newcombe</surname><given-names>PA</given-names></name><name><surname>Sheffield</surname><given-names>JK</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Minimally important change in a parent-proxy quality of life questionnaire for pediatric chronic cough (PC-QOL)</article-title><source>Chest</source><year>2010</year><volume>139</volume><fpage>576</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">20947650</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Watt</surname><given-names>JP</given-names></name><name><surname>O'Brien</surname><given-names>KL</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Bronsdon</surname><given-names>MA</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Dallas</surname><given-names>J</given-names></name><name><surname>Perilla</surname><given-names>MJ</given-names></name><name><surname>Reid</surname><given-names>R</given-names></name><name><surname>Murrow</surname><given-names>L</given-names></name><name><surname>Facklam</surname><given-names>R</given-names></name><name><surname>Santosham</surname><given-names>M</given-names></name><name><surname>Whitney</surname><given-names>CG</given-names></name><article-title>Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>4974</fpage><lpage>4976</lpage><pub-id pub-id-type="doi">10.1128/JCM.42.11.4974-4976.2004</pub-id><pub-id pub-id-type="pmid">15528682</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Stubbs</surname><given-names>E</given-names></name><name><surname>Hare</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>P</given-names></name><name><surname>Leach</surname><given-names>AJ</given-names></name><article-title>Streptococcus pneumoniae and noncapsular Haemophilus influenzae nasal carriage and hand contamination in children: a comparison of two populations at risk of otitis media</article-title><source>Pediatr Infect Dis J</source><year>2005</year><volume>24</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000160945.87356.ca</pub-id><pub-id pub-id-type="pmid">15876941</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Hare</surname><given-names>KM</given-names></name><name><surname>Morris</surname><given-names>P</given-names></name><name><surname>Smith-Vaughan</surname><given-names>H</given-names></name><name><surname>Leach</surname><given-names>AJ</given-names></name><article-title>Random colony selection versus colony morphology for detection of multiple pneumococcal serotypes in nasopharyngeal swabs</article-title><source>Pediatr Infect Dis J</source><year>2008</year><volume>27</volume><fpage>178</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">18174871</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Arden</surname><given-names>KE</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Lambert</surname><given-names>SB</given-names></name><name><surname>Nissen</surname><given-names>M</given-names></name><name><surname>Sloots</surname><given-names>TP</given-names></name><name><surname>Mackay</surname><given-names>IM</given-names></name><article-title>Newly identified respiratory viruses in children with asthma exacerbation not requiring admission into hospital</article-title><source>J Med Virology</source><year>2010</year><volume>82</volume><fpage>1458</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1002/jmv.21819</pub-id><pub-id pub-id-type="pmid">20572080</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Syrmis</surname><given-names>MW</given-names></name><name><surname>Whiley</surname><given-names>DM</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Mackay</surname><given-names>IM</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Siebert</surname><given-names>DJ</given-names></name><name><surname>Nissen</surname><given-names>MD</given-names></name><name><surname>Sloots</surname><given-names>TP</given-names></name><article-title>A sensitive, specific, and cost-effective multiplex reverse transcriptase-PCR assay for the detection of seven common respiratory viruses in respiratory samples</article-title><source>J Mol Diagn</source><year>2004</year><volume>6</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/S1525-1578(10)60500-4</pub-id><pub-id pub-id-type="pmid">15096568</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>McErlean</surname><given-names>P</given-names></name><name><surname>Shackelton</surname><given-names>LA</given-names></name><name><surname>Andrews</surname><given-names>E</given-names></name><name><surname>Webster</surname><given-names>DR</given-names></name><name><surname>Lambert</surname><given-names>SB</given-names></name><name><surname>Nissen</surname><given-names>MD</given-names></name><name><surname>Sloots</surname><given-names>TP</given-names></name><name><surname>Mackay</surname><given-names>IM</given-names></name><article-title>Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C)</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e1847</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0001847</pub-id><pub-id pub-id-type="pmid">18382652</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Ratcliff</surname><given-names>RM</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Kok</surname><given-names>T</given-names></name><name><surname>Sloots</surname><given-names>TP</given-names></name><article-title>Molecular diagnosis of medical viruses</article-title><source>Curr Issues Mol Biol</source><year>2007</year><volume>9</volume><fpage>87</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">17489437</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Petsky</surname><given-names>HL</given-names></name><name><surname>Acworth</surname><given-names>JP</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Winter</surname><given-names>D</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Asthma and protracted bronchitis: who fares better during an acute respiratory infection?</article-title><source>J Paediatr Child Health</source><year>2009</year><volume>45</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1754.2008.01433.x</pub-id><pub-id pub-id-type="pmid">19208065</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="book"><name><surname>Altman</surname><given-names>DG</given-names></name><source>Relation between several variables. In Practical Statistics for Medical Research</source><year>1991</year><publisher-name>London: Chapman &#x00026; Hall</publisher-name><fpage>326</fpage><lpage>364</lpage></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-32</pub-id><pub-id pub-id-type="pmid">20334632</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Torzillo</surname><given-names>PJ</given-names></name><name><surname>Boyce</surname><given-names>NC</given-names></name><name><surname>White</surname><given-names>AV</given-names></name><name><surname>Stewart</surname><given-names>PA</given-names></name><name><surname>Wheaton</surname><given-names>GR</given-names></name><name><surname>Purdie</surname><given-names>DM</given-names></name><name><surname>Wakerman</surname><given-names>J</given-names></name><name><surname>Valery</surname><given-names>PC</given-names></name><article-title>Zinc and vitamin-A supplementation in Indigenous children hospitalised with episodes of lower respiratory tract infection: a randomised controlled trial</article-title><source>Med J Aust</source><year>2006</year><volume>184</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">16460294</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Kolbe</surname><given-names>J</given-names></name><name><surname>Wells</surname><given-names>AU</given-names></name><article-title>Bronchiectasis: a neglected cause of respiratory morbidity and mortality</article-title><source>Respirology</source><year>1996</year><volume>1</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.1996.tb00037.x</pub-id><pub-id pub-id-type="pmid">9441110</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Tsang</surname><given-names>KW</given-names></name><name><surname>Bilton</surname><given-names>D</given-names></name><article-title>Clinical challenges in managing bronchiectasis</article-title><source>Respirology</source><year>2009</year><volume>14</volume><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2009.01569.x</pub-id><pub-id pub-id-type="pmid">19659645</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Bilton</surname><given-names>D</given-names></name><article-title>Non-cystic fibrosis bronchiectasis exacerbations</article-title><source>Thorax</source><year>2008</year><volume>63</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1136/thx.2006.060913</pub-id><pub-id pub-id-type="pmid">18308962</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Koh</surname><given-names>YY</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Sun</surname><given-names>YH</given-names></name><name><surname>Sung</surname><given-names>KW</given-names></name><name><surname>Chae</surname><given-names>JH</given-names></name><article-title>Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study</article-title><source>Eur Respir J</source><year>1997</year><volume>10</volume><fpage>994</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1183/09031936.97.10050994</pub-id><pub-id pub-id-type="pmid">9163637</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Wurzel</surname><given-names>D</given-names></name><name><surname>Marchant</surname><given-names>JM</given-names></name><name><surname>Yerkovich</surname><given-names>ST</given-names></name><name><surname>Upham</surname><given-names>JW</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>Short courses of antibiotics for children and adults with bronchiectasis</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><volume>6</volume><fpage>CD008695</fpage><pub-id pub-id-type="pmid">21678381</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>O'Donnell</surname><given-names>AE</given-names></name><name><surname>Barker</surname><given-names>AF</given-names></name><name><surname>Ilowite</surname><given-names>JS</given-names></name><name><surname>Fick</surname><given-names>RB</given-names></name><collab>rhDNase Study Group</collab><article-title>Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I</article-title><source>Chest</source><year>1998</year><volume>113</volume><fpage>1329</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1378/chest.113.5.1329</pub-id><pub-id pub-id-type="pmid">9596315</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Weller</surname><given-names>PH</given-names></name><name><surname>Spencer</surname><given-names>DA</given-names></name><article-title>Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome</article-title><source>Pediatr Pulmonol</source><year>1995</year><volume>20</volume><fpage>307</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1002/ppul.1950200509</pub-id><pub-id pub-id-type="pmid">8903903</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Loebinger</surname><given-names>MR</given-names></name><name><surname>Shoemark</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>M</given-names></name><name><surname>Kemp</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><article-title>Procalcitonin in stable and unstable patients with bronchiectasis</article-title><source>Chron Respir Dis</source><year>2008</year><volume>5</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1177/1479972308088823</pub-id><pub-id pub-id-type="pmid">18684791</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Courtney</surname><given-names>JM</given-names></name><name><surname>Kelly</surname><given-names>MG</given-names></name><name><surname>Watt</surname><given-names>A</given-names></name><name><surname>Garske</surname><given-names>L</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Ennis</surname><given-names>M</given-names></name><name><surname>Elborn</surname><given-names>JS</given-names></name><article-title>Quality of life and inflammation in exacerbations of bronchiectasis</article-title><source>Chron Respir Dis</source><year>2008</year><volume>5</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1177/1479972308091823</pub-id><pub-id pub-id-type="pmid">18684792</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Proud</surname><given-names>D</given-names></name><name><surname>Chow</surname><given-names>CW</given-names></name><article-title>Role of viral infections in asthma and chronic obstructive pulmonary disease</article-title><source>Am J Respir Cell Mol Biol</source><year>2006</year><volume>35</volume><fpage>513</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2006-0199TR</pub-id><pub-id pub-id-type="pmid">16778148</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Hutchinson</surname><given-names>AF</given-names></name><name><surname>Black</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Bozinovski</surname><given-names>S</given-names></name><name><surname>Brand</surname><given-names>CA</given-names></name><name><surname>Smallwood</surname><given-names>DM</given-names></name><name><surname>Irving</surname><given-names>LB</given-names></name><name><surname>Anderson</surname><given-names>GP</given-names></name><article-title>Identifying viral infections in vaccinated chronic obstructive pulmonary disease (COPD) patients using clinical features and inflammatory markers</article-title><source>Influenza Other Respi Viruses</source><year>2010</year><volume>4</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2009.00113.x</pub-id><pub-id pub-id-type="pmid">20021505</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>MP</given-names></name><name><surname>Turnbull</surname><given-names>K</given-names></name><name><surname>Macquarrie</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name><article-title>Assessing response to treatment of exacerbations of bronchiectasis in adults</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">18829674</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Masters</surname><given-names>IB</given-names></name><name><surname>Newcombe</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><article-title>The burden of disease in pediatric non-cystic fibrosis bronchiectasis</article-title><source>Chest</source><year>2012</year><volume>141</volume><fpage>1018</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1378/chest.11-0679</pub-id><pub-id pub-id-type="pmid">21885727</pub-id></mixed-citation></ref></ref-list></back></article>